[Estimates of Target Population for Pneumococcal Vaccination in People over 50 Years in Catalonia and Spain]

Overview

Journal Rev Esp Salud Publica

Specialty Public Health

Date 2017 Mar 17

PMID 28300793

Authors

Angel Vila-Corcoles

Olga Ochoa-Gondar

Eva Satue

Cinta de Diego

Marc Vila-Rovira

Manel Jariod

Affiliations

Soon will be listed here.

Abstract

Objective: Published data about prevalence of distinct risk condictions for pneumococcal disease is scarce. This study investigated the prevalence of distinct risk conditions for pneumococal disease in Catalonian adults and stimated the potential size of target population for pneumococcal vaccination in Catalonia and Spain.

Methods: Cross-sectional population-based study that included 2,033,465 individuals older than 49 years-old assigned to the Catalonian Health Institute (Catalonia, Spain) at 01/01/2015. The Catalonian Health Institute Information System for the Development of Research in Primary Care (SIDIAP) was used to identify comorbidities and/or underlying conditions in each subject and establish potential target population for pneumococcal vaccination on the basis of their risk for suffering pneumococcal infections: 1) immunocompromised subjects; 2) immunocompetents subjects with any risk condition; 3) immunocompetents subjects without risk conditions.

Results: Of the 2,033,465 study subjects, 1,053,155 (51.8%) had no risk conditions, 649,014 (31.9%) had one risk condition and 331,296 (16.3%) had multiple risk conditions (11.4% in 50-64 years vs 21.2% in people older than 65 years, p smaller than 0.001; 21.8% in men vs 11.6% in women, p smaller than 0.001). Overall, 176,600 (8.7%) and 803,710 (39.5%) were classified in risk stratum 1 and 2, respectively. According to distinct risk strata considered, the target population for pneumococcal vaccination varied between 0.2-1.9 million in Catalonia and 1.5-2.3 million in Spain.

Conclusions: In our setting, almost fifty percent of people ≥50 years have at least one risk condition to suffert pneumococcal disease. Adult population susceptible for pneumococal vaccination largely varies depending on the risk stratum considered as targeted people for pneumococcal vaccination.

References

van Hoek A, Andrews N, Waight P, Stowe J, Gates P, George R . The effect of underlying clinical conditions on the risk of developing invasive pneumococcal disease in England. J Infect. 2012; 65(1):17-24. DOI: 10.1016/j.jinf.2012.02.017. View

Vila Corcoles A, Ochoa Gondar O, Ansa Echeverria X, Blade Creixenti J, Palacios Llamazares L, Fuentes Bellido C . [Coverage and association with clinical variables of antipneumococcal vaccination of the population over 65 years old in Tarragona-Valls]. Rev Esp Salud Publica. 2006; 79(6):645-54. DOI: 10.1590/s1135-57272005000600004. View

. Use of 13-valent pneumococcal conjugate vaccine and 23-valent pneumococcal polysaccharide vaccine for adults with immunocompromising conditions: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Morb Mortal Wkly Rep. 2012; 61(40):816-9. View

Tomczyk S, Bennett N, Stoecker C, Gierke R, Moore M, Whitney C . Use of 13-valent pneumococcal conjugate vaccine and 23-valent pneumococcal polysaccharide vaccine among adults aged ≥65 years: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Morb Mortal Wkly Rep. 2014; 63(37):822-5. PMC: 5779453. View

. Updated recommendations for prevention of invasive pneumococcal disease among adults using the 23-valent pneumococcal polysaccharide vaccine (PPSV23). MMWR Morb Mortal Wkly Rep. 2010; 59(34):1102-6. View

Bolibar B, Fina Aviles F, Morros R, Garcia-Gil M, Hermosilla E, Ramos R . [SIDIAP database: electronic clinical records in primary care as a source of information for epidemiologic research]. Med Clin (Barc). 2012; 138(14):617-21. DOI: 10.1016/j.medcli.2012.01.020. View

Vila-Corcoles A, Aguirre-Chavarria C, Ochoa-Gondar O, de Diego C, Rodriguez-Blanco T, Gomez F . Influence of chronic illnesses and underlying risk conditions on the incidence of pneumococcal pneumonia in older adults. Infection. 2015; 43(6):699-706. DOI: 10.1007/s15010-015-0801-y. View

Kyaw M, Rose Jr C, Fry A, Singleton J, Moore Z, Zell E . The influence of chronic illnesses on the incidence of invasive pneumococcal disease in adults. J Infect Dis. 2005; 192(3):377-86. DOI: 10.1086/431521. View

Lynch 3rd J, Zhanel G . Streptococcus pneumoniae: epidemiology and risk factors, evolution of antimicrobial resistance, and impact of vaccines. Curr Opin Pulm Med. 2010; 16(3):217-25. DOI: 10.1097/MCP.0b013e3283385653. View

10.

Nuorti J, Butler J, Farley M, Harrison L, McGeer A, Kolczak M . Cigarette smoking and invasive pneumococcal disease. Active Bacterial Core Surveillance Team. N Engl J Med. 2000; 342(10):681-9. DOI: 10.1056/NEJM200003093421002. View

11.

Ortqvist A, Hedlund J, Kalin M . Streptococcus pneumoniae: epidemiology, risk factors, and clinical features. Semin Respir Crit Care Med. 2006; 26(6):563-74. DOI: 10.1055/s-2005-925523. View

12.

Garcia-Gil M, Hermosilla E, Prieto-Alhambra D, Fina F, Rosell M, Ramos R . Construction and validation of a scoring system for the selection of high-quality data in a Spanish population primary care database (SIDIAP). Inform Prim Care. 2012; 19(3):135-45. DOI: 10.14236/jhi.v19i3.806. View

13.

Picazo J, Gonzalez-Romo F, Garcia Rojas A, Perez-Trallero E, Gregorio P, de la Camara R . [Consensus document on pneumococcal vaccination in adults with risk underlying clinical conditions]. Rev Esp Quimioter. 2013; 26(3):232-52. View

14.

Dworkin M, Ward J, Hanson D, Jones J, Kaplan J . Pneumococcal disease among human immunodeficiency virus-infected persons: incidence, risk factors, and impact of vaccination. Clin Infect Dis. 2001; 32(5):794-800. DOI: 10.1086/319218. View